AUC difference
-0.0017 AUC difference
- EndpointENV-SOC versus ENV-ECS reader-study AUC
- Population1,475 DBT subjects from 15 locations
- Tested versionGenius AI Detection 2.0 submitted in K243341; build not stated
FDA-cleared profile
Hologic, Inc. · Mammography/DBT · FDA-cleared (510(k))
Authorized purpose: Genius AI Detection 2.0 analyzes compatible digital breast tomosynthesis exams to identify and mark soft-tissue densities (masses, architectural distortions, asymmetries) and calcifications, providing lesion location/outline, confidence or Certainty of Findings, and a case score for concurrent review; the interpreting physician confirms or dismisses findings.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: Genius AI Detection 2.0 analyzes compatible digital breast tomosynthesis exams to identify and mark soft-tissue densities (masses, architectural distortions, asymmetries) and calcifications, providing lesion location/outline, confidence or Certainty of Findings, and a case score for concurrent review; the interpreting physician confirms or dismisses findings.
Evidence takeaway. Evidence from the reviewed source record: Retrospective multicenter validation included 1,475 subjects from 15 locations with biopsy-proven cancers, benign cases, screening-negative cases, and diagnostic cases; the FDA packet reports no significant ENV-SOC versus ENV-ECS reader-study AUC difference.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
-0.0017 AUC difference
76 percent
67 percent
K243341
Two MQSA radiologists interpreted cases; a separate implant subset contained 480 cases.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Price not public here; enter your quote
Not verified: Pricing information is recorded but not verified against a resolving source.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: Compatible digital breast tomosynthesis exams, including 1 mm Clarity HD and 6 mm SmartSlices from the Hologic Envision platform and compatible Hologic Selenia Dimensions exams; DICOM input is described.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-06 · FDA 510(k) K243341: Genius AI Detection 2.0
Source context, not route validation: The submission describes DICOM Mammography CAD SR output for DICOM-compliant review workstations and worklist use; local Hologic platform, workstation, and version compatibility require confirmation.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-06 · FDA 510(k) K243341: Genius AI Detection 2.0
Source context, not route validation: The exact FDA package describes the subject device's deployment as a stand-alone computer, with a softcopy workstation as the output device. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Features and Subject Device Predicate Device Difference and" … "Output Device Softcopy Workstation Same N/A Deployment Stand-alone computer Same N/A". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-11-14 · FDA 510(k) K243341: Genius AI Detection 2.0
Source context, not route validation: Lesion location, lesion outline, Certainty of Findings confidence score, and an exam-level Case Score, packaged as a DICOM Mammography CAD SR for display on DICOM-compliant review workstations; findings include soft-tissue densities and calcifications.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-06 · FDA 510(k) K243341: Genius AI Detection 2.0
Unresolved route: Lesion location, lesion outline, Certainty of Findings confidence score, and an exam-level Case Score, packaged as a DICOM Mammography CAD SR for display on DICOM-compliant review workstations; findings include soft-tissue densities and calcifications.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-06 · FDA 510(k) K243341: Genius AI Detection 2.0
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Packet wording: "Features and Subject Device Predicate Device Difference and" … "Output Device Softcopy Workstation Same N/A Deployment Stand-alone computer Same N/A". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Vendor statement, not an attestation. Page scope is Hologic's Breast and Skeletal Health division; this entry is a mammography/DBT product within that division. Exact-release scope is not established.
Vendor statement, not an attestation. The page scopes to Hologic Breast & Skeletal products generally and does not scope this process to any specific product release; exact-release scope is not established.
The exact submission packages findings as a DICOM Mammography CAD SR for DICOM-compliant review workstations and worklist display.
exact submission · checked 2026-09-06Hologic's official Genius family page describes display through SecurView 12.0 and worklist workflow; exact K243341 deployment and local compatibility require confirmation.
product family · checked 2026-09-07Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
No stored PubMed or ClinicalTrials.gov candidate identifiers for this submission in the 2026-09-01 snapshot; exact-submission recall candidate review was also zero. This metadata screen is not a full paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, literature index, trial registry, fda device recall, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
No public amount, range, currency, geography, or contract term was established.
Bounded web search on 2026-10-26 (query: "Hologic Genius AI Detection reimbursement CPT mammography"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Hologic's 2026 Mammography Coding Guide (MISC-03286 REV 016) was read; it lists CPT 77065-77067 and does not name Genius AI Detection, so it is kept as a lead. This records what was found, not that none exists.
Current onboarding, competency, and support commitments were not established.
8 sources - 3 history items
Scope: identity, purpose, clinicalUse, modality, anatomy, input, output, limitations, integration, deployment, evidenceSummary, evidenceMetrics, evidenceStudies
Scope: regulatoryIdentity, modalityContext
Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: recallDiscovery, nativeSubmissionMatching
Scope: productFamilyWorkflow, implementationCapabilities
Scope: security
Regulatory record
510(k)
Research record
human reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
DeepHealth, Inc.
Authorized purpose: Concurrent detection and characterization support for screening DBT mammography
Lunit, Inc.
Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.
Lunit, Inc.
Authorized purpose: Concurrent CADe/x aid for interpreting physicians to detect and characterize breast-cancer-suspicious lesions in screening DBT exams from compatible systems, marking soft-tissue lesions and calcifications with abnormality scores.
Clairity, Inc.
Authorized purpose: Allix5 generates a five-year breast-cancer-risk prediction from bilateral screening mammograms for eligible patients without known breast cancer at presentation; it is not intended to diagnose or detect cancer, recommend care, or serve as the sole determinant of care.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history